Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
Ronald Scott, Basilea's Chief Executive Officer, indicated: "Basilea greatly appreciates Ms. McDaid who built Basilea's human resources department and operations from our founding to a level of industry excellence. Basilea's human resources activities will continue to be in good hands under Ms. Eberhardt, who has been our deputy Head of Global Human Resources for the last seven years. We wish Ms. McDaid all the best in her retirement and much success to Ms. Eberhardt in her new position."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 [email protected] [email protected] |
This press release can be downloaded from www.basilea.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d56fddc3-2502-430d-adbc-9a2ff077d4bd


Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 



